Citations

Clear

16280 citation(s) found for "Yu, David".

Postoperative ctHPVDNA Kinetics in Patients With HPV-Related Oropharyngeal Cancer
Hidalgo, C. , Bogan, Aaron, Hunter, Danielle E., Tasche, Kendall K. , Moore, Eric J. , Neben-Wittich, M.A. , Price, Katharine A., Bayne, Harry E. Fuentes, Abel, Kathryn M. Van , Hidalgo, Cecelia M, Bogan, Aaron W, Bartemes, Kathleen R. , Neben-Wittich, Michelle A, Lester, Scott C. , McGarrah, Patrick W. , Fuentes Bayne, Harry E, Van Abel, Kathryn M , Yin, Linda X. , Price, Daniel L. , Daniel, J. , Routman, David M.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | May 14, 2025 | Volume: 151 | Issue: 12 | Pages: 1117

10.1001/jamaoto.2025.1606 | PMID 40367049 Get It

Importance Circulating tumor human papillomavirus DNA (ctHPVDNA) is an important biomarker for the presence of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), but little is known about early postoperative kinetics of ctHPVDNA clearance. Objective To investigate early postoperative kinetics of ctHPVDNA in patients with HPV-associated OPSCC. Design, Setting, and Participants This prospective cohort study was conducted at a single tertiary care center from January 4, 2020, to January 26, 2023. Patients with newly diagnosed HPV-associated OPSCC undergoing surgical management were enrolled. HPV status was defined as positive if findings of p16 immunohistochemistry and/or HPV DNA in situ hybridization and/or E6/E7 RNA in situ hybridization were positive. Exclusion criteria included history of prior head and neck cancer and metastatic disease at presentation. Data were analyzed from September 1, 2024, to April 25, 2025. Exposures Transoral robotic surgery with concurrent neck dissection. Main Outcomes and Measures Blood was drawn prior to surgery (pretreatment), 1 to 2 days after surgery (postoperative days 1 to 2), and approximately 2 weeks after surgery (postoperative week 2; range, 8 to 20 days). ctHPVDNA was quantified by a tumor tissue–modified viral (TTMV) HPV DNA test. Correlations were tested between the pretreatment and postoperative day 1 to 2 TTMV HPV DNA levels using Gaussian regression. Concordance between detectability at postoperative day 1 to 2 and postoperative week 2 was explored using negative predictive value and positive predictive value. Results Of 57 included patients with detectable pretreatment TTMV HPV DNA, 51 (89%) were male, and the median (IQR) age was 59 (54-66) years. A total of 35 patients (61%) had blood draws at all 3 time points; 16 (28%) had detectable TTMV HPV DNA on postoperative day 1 to 2. Pretreatment and postoperative day 1 to 2 TTMV HPV DNA levels had a medium positive linear correlation ( r = 0.31; 95% CI, 0.04-0.54). Undetectable TTMV HPV DNA on postoperative day 1 to 2 blood draw had a negative predictive value of 0.95 (95% CI, 0.74-1.00) for an undetectable level on postoperative week 2 blood draw, but a detectable level on postoperative day 1 to 2 blood draw only had a positive predictive value of 0.19 (95% CI, 0.04-0.46). Of the 16 patients with detectable TTMV HPV DNA pretreatment and at postoperative day 1 to 2, only 3 (19%) continued to have detectable TTMV HPV DNA at postoperative week 2. One patient had undetectable levels at postoperative day 1 to 2 and detectable levels at postoperative week 2. Conclusions and Relevance In this study, ctHPVDNA detectability early after surgery did not predict detectability at 2 weeks after surgery. ctHPVDNA clearance early after surgery could predict a negative test at 2 weeks. A negative blood draw finding on postoperative day 1 may be used to omit a postoperative blood draw at 2 weeks for minimal residual disease detection in future clinical trials.
Subclinical Atherosclerosis and Cardiovascular Events Among Patients With Colorectal Cancer
Levy, Julia , Kazemian, Elham, Loroña, Nicole C. , Nadri, Maimoona, Gasho, Jordan , Silos, Katrina D., Nikolova, Andriana , Dey, Damini , Siegel, Erin M. , Hardikar, Sheetal , Byrd, Doratha A. , Shibata, David , Tamarappoo, Balaji , Atkins, Katelyn M. , Figueiredo, Jane C. , Loroña, Nicole C , Gasho, Jordan O , Hardikar, Sheetal , Toriola, Adetunji T , Li, Christopher I , Ulrich, Cornelia M , Tamarappoo, Balaji K, Figueiredo, Jane C , Dey, Damini , Ramin, Cody A. , Gigic, Biljana , Toriola, Adetunji T. , Ose, Jennifer , Ulrich, Cornelia M.

Mayo Clinic

Cancer Medicine | May 14, 2025 | Volume: 14 | Issue: 10 | Pages: No page available

10.1002/cam4.70938 | PMID 40365909 Get It

ABSTRACTBackgroundPrior studies have documented that patients with colorectal cancer (CRC) are at an increased risk of cardiovascular disease (CVD).ObjectivesTo examine coronary artery calcium (CAC) as a marker of subclinical atherosclerosis and its association with major adverse cardiovascular events (MACE) in patients with CRC across the cancer treatment trajectory.MethodsAdults with newly diagnosed CRC were enrolled in the prospective ColoCare study from 2017 to 2024. CAC was measured from routine diagnostic computed tomography (CT) and positron emission tomography‐CT scans at CRC diagnosis until 5 years post‐diagnosis. Atherosclerosis was defined as the presence of CAC. We used multivariable‐adjusted Fine and Gray models to assess the association between CAC and MACE risk, accounting for competing risks.ResultsAmong 300 CRC patients, the most common CVD risk factors at cancer diagnosis were hypertension (37%), hyperlipidemia (24%), and diabetes (14%). During follow‐up (median = 5.3 years), 75 (25%) individuals experienced MACE: stroke (3%), new/worsening HF (9%), HF exacerbation requiring hospitalization (2%), coronary revascularization (3%), and death (19%). Among individuals with imaging at baseline (n = 101), 37 (36.6%) had CAC, and statins were not prescribed in 11 (55.0%) patients with moderate/high CAC. For those with serial imaging (n = 61), 31.1% showed worsening CAC and 3% developed new CAC. Baseline CAC conferred a higher risk of MACE (HR = 4.79; 95% CI: 1.05–21.75, p = 0.04) after accounting for cancer‐related deaths as a competing risk.ConclusionsSubclinical atherosclerosis and MACE are common among patients with CRC. Integrating CAC from routine cancer imaging can identify patients who may benefit from cardio‐preventive treatment.
Risk of adalimumab‐induced psoriasis in hidradenitis suppurativa versus other inflammatory diseases
Tran, Tung S, Nguyen, Trang M , Arment, Courtney A. , Alavi, Afsáneh , Wetter, David A., Nguyen, Giang Huong , Tran, Tung S. , Tran, Tung S , Nguyen, Trang M , Alavi, A , Nguyen, Giang H , Nguyen, Anh Tuan , Loftus, Edward V. , Doanh, Le Huu , Wetter, David A.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | May 14, 2025 | Volume: 40 | Issue: 2 | Pages: No page available

10.1111/jdv.20743 | PMID 40365816 Get It

From embedded interprofessional clinics to expanded alcohol-associated liver disease programs
Winder, Gerald Scott , Banerjee, Arpita Goswami, Bryce, Kelly , Fipps, David C. , Hussain, Filza, Omary, Lesley, Patel, Shivali , Rubman, Susan , Shenoy, Akhil , Suzuki, Joji , Zimbrean, Paula C. , Brown, Kimberly , Mellinger, Jessica L. , Hussain, Filza , Im, Gene , Patel, Arpan , Serper, Marina , Shenoy, Akhil , Suzuki, Joji , Abouljoud, Marwan , Mellinger, Jessica , Winder, Scott , Fipps, David C , Arab, Juan Pablo , Patel, Arpan , Serper, Marina

Mayo Clinic

Liver Transplantation | May 13, 2025 | Volume: 31 | Issue: 12 | Pages: 1567-1580

10.1097/lvt.0000000000000638 | PMID 40359009 Get It

Hazardous alcohol use remains a major contributor to acute and chronic liver disease, while alcohol-associated liver disease (ALD) is a leading indication for liver transplantation. In recent years, embedded, interprofessional ALD clinics have improved access to alcohol use disorder care within hepatology and liver transplantation, but more work is needed to meet this challenge. The literature is lacking regarding scaling procedures to provide services for increasingly large ill patient populations. This article begins to fill this gap by describing “expanded ALD care”: broad, innovative, longitudinal, interprofessional care delivery strategies surpassing standalone clinics. Drawing from analogous patient populations served by collaborative models in primary care and comprehensive eating disorder treatment, the expanded ALD care framework proposes practical strategies toward specific innovations: equipoise between biomedical and psychosocial care elements, increased clinician number and reach, long-term patient relationships, harm reduction and palliative care, outreach to external agencies and clinicians, and enhanced support for patients and families. The article also defines attributes of innovative healthcare systems that support expanded ALD care.
Plasma-CycleGAN: Plasma Biomarker-Guided MRI to Pet Cross-Modality Translation Using Conditional CycleGAN
Chen, Yanxi , Dumitrascu, Celine, Weidman, David, Caselli, Richard J., Reiman, Eric M. , Su, Yi , Chen, Kewei , Caselli, Richard J. , Ashton, Nicholas J. , Wang, Yalin

Mayo Clinic

2025 IEEE 22nd International Symposium on Biomedical Imaging (ISBI) | May 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1109/isbi60581.2025.10980900 | PMID 40822978 Get It

Small intestinal microbial fiber metabolism dysfunction in celiac disease
Verdú, Elena F. , Wulczynski, Mark, Blom, Jedid-Jah , Rueda, Gaston , El-Chaar, Nader N., Superdock, Dorothy K. , Jiang, Sharon, David, Lawrence A. , Armstrong, David , Berčík, Přemysl , El-Chaar, N , Superdock, D K , David, L A , Surette, M G , Bercik, Premysl , Caminero, A , Verdu, Elena F , Constante, Marco , Galipeau, Heather J. , Rueda, Gaston H., Murray, Joseph A. , Armstrong, David , Pinto-Sánchez, María Inés , Caminero, Alberto

Mayo Clinic

No container title available | May 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6572358/v1 | PMID 40470242 Get It

Abstract Celiac disease (CeD) is an immune-mediated condition driven by dietary gluten resulting in small intestinal mucosal inflammation and injury, along with myriads of symptoms. The only treatment is a lifelong gluten-free diet (GFD) and although most patients improve, the restriction can lead to nutrient deficiencies including fiber. While duodenal microbiota is altered in CeD, its fiber metabolic capacity is unknown. Here we show that both active and GFD-treated CeD patients had impaired microbial fiber metabolism in the small intestine which associates with depletion of the carbolytic taxa Prevotella spp. Colonization of germ-free mice with Prevotella spp increased small intestinal short chain fatty acids (SCFA). In gluten-sensitized mice expressing the celiac risk gene, HLA-DQ8, an inulin-supplemented diet facilitated microbial carbolytic function, SCFAs production and accelerated mucosal healing in the small intestine during GFD. The results support clinical investigations of dietary fiber supplementation and microbial carbolytic function to enhance responses to GFD in CeD.
Harmonized Assessment and Quality Control of Quantitative Measures of Lung Structure on Pre-pandemic Cardiac and Lung Computed Tomography (CT) Scans for Large-scale Investigation of Risk of Long COVID-19: The Collaborative Cohort of Cohorts for COVID-19 Re
Naik, Seema , Smith, B.M. , Cheng, T.-K., Lynch, David A. , Matsushita, Kunihiro , O'Driscoll, O., Ortega, Victor E. , Washko, George R. , Laine, Andrew F. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Naik, S., Allen, Norrina B. , Balte, Pallavi , Blaha, Michael Joseph , Budoff, Matthew J. , Carr, J. Jeffrey , Carson, April P. , Cheng, T.-K., Estépar, Raúl San Jośe , Hoffman, Eric A. , Humphries, Stephen M. , Kanaya, Alka M , Kandula, Namratha R. , O’Connor, George T. , Pottinger, Tess D. , Schwartz, David A. , Wenzel, Sally E. , Xanthakis, Vanessa , Angelini, Elsa D. , Barr, R. Graham

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7658-A7658

10.1164/ajrccm.2025.211.abstracts.a7658 Get It

Abstract RATIONALE: Susceptibility to severe COVID-19 and long COVID may be influenced by pre-existing lung structure. ECG-gated, non-contrast cardiac CT scans, originally acquired for assessing coronary artery calcium, are available in multiple longitudinal cohort studies and have been previously validated against lung CT scans for densitometry; however, protocol variation across cohorts may hinder direct comparison. To address this, we developed a quality control (QC) rubric to grade cardiac CT scans for standardized quantitative lung measures across cohorts. METHODS: C4R assessed SARS-CoV-2 infection and outcomes in 14 NHLBI cohorts, of which 10 (six community-based and four longitudinal case-control studies) included CT scans (12,459 participants with lung and 13,752 with cardiac CTs). Logic rules were applied to categorize scans (Table): Grade “A-B” scans had 2-3.5mm slice thickness, at least 20 axial slices, no lung cropping in axial view and lung and airway volumes greater than the cohort-specific 1st percentile. “C-D” scans had one lung obscured by cropping around the heart, so quantitative measures were restricted to the lung in complete view. “F-H” scans were deemed unusable, suffering from low slice count (<20), severe image cropping, low lung or airway volumes (< 1st%ile). Visual inspection was performed on a sample from each category to ensure accuracy. Percent of lung voxels in low attenuation areas < -950 HU (LAA950), high attenuation areas (-600 to -250 HU, HAA) and 15th percentile HU value (perc15) were measured. Within-participant variability was quantified using the intraclass correlation coefficient (ICC). RESULTS: We performed QC on cardiac CT scans from an initial sample of 6,275 participants from three C4R cohorts (ARIC, CARDIA, MASALA), imaged with GE or Siemens scanners. Of these, 5,125 (81.7%) were graded “A-B”, 496 (7.9%) were “C-D” and 654 (10.4%) were “F-H”. The percentage of “F-H” scans varied widely across cohorts [<1% to 26%] due to image cropping. Among the 5,621 cardiac CT scans graded A-D, the mean±SD for LAA950, HAA and perc15 respectively were 1.1±2.1%, 7.2±4.7% and -887±33 HU. Repeated imaging was available for 107 participants (time interval 5.1±0.7y). For paired scans in grades A-B (n=101/107), the within-participant correlation for LAA950, HAA and perc15 were 0.91, 0.38 and 0.74 respectively. CONCLUSION: Initial application of QC to cardiac CT scans identified scans with high reproducibility, with the aim to provide valid quantitative lung metrics on over 20,000 highly characterized participants in C4R.
Differences in COVID-19 Vaccination Behaviors Among Adults With Versus Without Chronic Lower Respiratory Diseases: The C4R Study
Lawin, K., Norwood, Arnita F. , Stukovsky, Karen Hinckley , Elkind, Mitchell S, Ortega, Victor E. , Lopez, Victor , Zhang, Ying , Fretts, Amanda M. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Wang, Timothy C. , Lawin, K., Kucharska‐Newton, Anna , Demmer, Ryan T. , Jacobs, David R. , Regan, Elizabeth Anne , Lee, Joyce , Xanthakis, Vanessa , Isasi, Carmen R. , Kanaya, Alka M , Post, Wendy S. , Howard, Virginia J. , Lopez, V., Balte, Pallavi

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7464-A7464

10.1164/ajrccm.2025.211.abstracts.a7464 Get It

Abstract RATIONALE: Chronic lower respiratory diseases (CLRD) confer higher risks from respiratory viral infections, hence CLRD patients are prioritized for influenza, pneumococcal, and COVID-19 vaccination. Nonetheless, vaccine deferral and declination remain common. Given that COVID-19 vaccination is particularly polarizing, and attitudes toward it may differ from other vaccines, we assessed COVID-19 vaccination behaviors and attitudes in adults with versus without CLRD and/or smoking history, which is strongly associated with CLRD risk. METHODS: We pooled data from 10 cohorts participating in the Collaborative Cohort of Cohorts for COVID-19 Research (C4R) that collected pre-pandemic data on self-reported physician diagnosis of asthma or COPD. C4R assessed COVID-19 vaccination status through three waves of standardized questionnaires (2020-2022, 2021-2023, 2023-2024). Prompt COVID-19 vaccination was defined as self-report of receiving at least one COVID-19 vaccine by May 1, 2021. Cumulative COVID-19 vaccine count was self-reported on the Wave 3 Questionnaire. Vaccine attitudes and receipt of influenza and/or pneumococcal vaccines were self-reported on the Wave 1 or 2 Questionnaire. Age-adjusted Poisson regression was used to test associations of vaccination behaviors with CLRD and smoking status at the most recent pre-pandemic exam. RESULTS: Of 20,034 participants (pre-pandemic COPD, 9.3%; asthma, 11.7%; current smoking, 13.4%; former smoking, 36.3%), 64.2% reported prompt COVID-19 vaccination. Among the subset of 10,626 participants completing the Wave 3 Questionnaire in 2023-24, the median COVID-19 vaccine count was 3 (Q1:2, Q3:4). Compared to participants without CLRD, prompt vaccination was more likely in those with asthma (RR=1.04, 95%CI:1.01-1.07, p=0.008) and less likely with COPD (RR=0.94, 95%CI:0.91-0.98, p=0.001), but there were no differences in doses for asthma and COPD. Compared to never smokers, former smoking participants were more likely to receive prompt vaccination (RR=1.11, 95%CI:1.08-1.13, p<0.0001) and more vaccine doses (RR=1.03, 95%CI:1.01-1.05, p=0.015); conversely, current smoking was inversely associated with prompt vaccination (RR=0.94, 95%CI:0.91-0.97, p=0.001) and was associated with fewer doses (RR=0.93, 95%CI:0.89-0.96, p<0.0001). Participants with CLRD versus without CLRD were more likely to report receiving influenza and pneumococcal vaccines, but they were more likely to believe that vaccines are unsafe or ineffective (figure). CONCLUSIONS: COPD was associated with lower likelihood of prompt COVID-19 vaccination. Current smoking was associated with both lower likelihood of prompt COVID-19 vaccination and a lower number of COVID-19 vaccine doses by 2023-24. These associations may be partly attributed to negative vaccine attitudes and beliefs. How the COVID-19 pandemic may have influenced vaccine behaviors and attitudes merits additional study.
Differences in Airway Epithelial Gene Expression in Resilient vs Non-resilient Smokers
Oh, Anna , Niederhuber, Matthew J. , Jones, Corbin D. , Brennan, Tara A., Currin, Kevin W., Kennedy, Sarah , Christenson, S., Bon, Jessica , Comellas, Alejandro P. , Cooper, C.B., Hansel, N.N., Kaner, R.J. , Marchetti, Nathaniel , Onofrei, C.D., Ortega, Victor E. , Paine, Robert , Woodruff, P., Investigators, SPIROMICS, Christenson, Stephanie A. , Comellas, Alejandro P , Christenson, Stephanie A , Oh, A., Liu, Heng , Kennedy, S., Couper, David , Barjaktarević, Igor , Barr, R. Graham , Bowler, Russell P. , Cooper, C.B. , Han, Mingyuan , Krishnan, Jerry A , Martínez, Fernando J. , Wells, J. Michael

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7375-A7375

10.1164/ajrccm.2025.211.abstracts.a7375 Get It

Abstract Introduction Resilient smokers, who maintain respiratory health despite smoking, remain poorly characterized. Airway epithelial cell gene expression in resilient smokers can provide insight into mechanisms and pathways that may protect smokers from developing smoking-related lung disease. The objective of this study is to identify genes and potential pathways associated with lung-related resilience. Methods Resilient smokers were defined based on a previously published multi-dimensional definition which includes the absence of: 1) spirometric airflow limitation, 2) symptoms (cough/sputum, dyspnea), 3) radiographic (HRCT) abnormalities, 4) exacerbations, and 5) an accelerated FEV1 decline. “Non-resilient” smokers had preserved spirometry but showed abnormalities in at least one domain of resilience. We analyzed airway epithelial brush samples from 21 resilient and 34 non-resilient smokers from SPIROMICS. Differential gene expression was performed using DESeq2 package in R, which estimates differential expression using generalized linear models. We adjusted for sequencing batch, age (continuous), race, gender, and current smoking status. While controlling for these covariates we evaluated differential gene expression between resilient and non-resilient smokers, the interaction between resilience and smoking status, and in each sub-category of resilient (absence of symptoms, radiographic abnormalities, exacerbations, and accelerated decline in FEV1). Results We identified 98 genes that were differentially expressed (FDR ≤0.1) when comparing resilient to non-resilient smokers, 20 of those genes were up regulated in resilient smokers (Figure 1). Notable genes included cadherin-12 (CDH12), aspartate beta-hydroxylase (ASPH), and protein kinase AMP-activated alpha 2 (PRKAA2). CDH12 is involved in cell adhesion and epithelial integrity. ASPH influences cell adhesion and signaling. PRKAA2 plays role in cellular homeostasis and stress response, which may be altered in non-resilient smokers, affecting cellular metabolism and inflammation. BPI folding containing family A member (BPIFA1) was significantly associated with smoking status in the interaction analysis, suggesting its role in modulating the impact of smoking on resilience. BPIFA1 has anti-microbial properties, regulates immune responses, and contributes mucosal surface protection. Sub-category analysis identified 17 genes associated with resilience to symptoms and 2 genes related to physiologic resilience (FEV1 decline), though no significant genes were associated with radiographic or exacerbation resilience. Conclusion Differential gene expression of airway epithelial cells identified distinct expression patterns between resilient and non-resilient smokers. Specifically, genes associated with epithelial cell adhesion, signaling, and cellular homeostasis were up regulated in resilient smokers. These findings suggest that resilient smokers may have transcriptomic profiles and potential mechanisms that mitigate the effects of cigarette smoke.
Male Survival Disadvantage in Pulmonary Hypertension in the PVRI Godeep Meta-registry
Annis, Jeffrey , Meike, F., Wilhelm, Jochen , Kiely, David G. , Balasubramanian, A., Eichstaedt, Christina A. , Zamanian, Roham T. , Elwing, Jean , Pepke-Zaba, J., Hernandez, Nadia , Frauendorf, Marlize , Williams, Paul , Anthi, Anastasia , Dima, Efrossini, Majeed, Rehan, Tello, Khodr , Kiely, David , Yogeswaran, Athiththan , Howard, Luke , Lawrie, Allan , Wilkins, Martin R. , Balasubramanian, A. , Hassoun, Paul M. , Grünig, Ekkehard , Sweatt, Andrew J. , Kovács, Gábor , Olschewski, Horst , Ghouleh, Imad Al , Chan, Stephen Y. , Jose, Arun , Cannon, J., Pepke-Zaba, J., Frantz, Robert P. , Sіrenko, Yu.M. , Torbas, O.O. , Sahay, Sandeep , Hernandez, N., Arvanitaki, Alexandra , Giannakoulas, George , Sabbour, Hani Mohamed , Saleh, Khaled Musa Mohammad , Ghio, Stefano , Scelsi, Laura , Majeed, R., Ghofrani, Hossein Ardeschir , Grimminger, Friedrich , Cajigas, Héctor , Brittain, Evan L , Seeger, Werner

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A7097-A7097

10.1164/ajrccm.2025.211.abstracts.a7097 Get It

Abstract Introduction Sex-based differences in morbidity and mortality for pulmonary hypertension (PH) are insufficiently addressed in current research. However, recognizing these differences is crucial for optimal clinical management and improving outcomes. This study assesses the effect of sex on survival among PH patients, while accounting for disease severity, comorbidities, treatment, and race. Methods We analyzed data from the PVRI GoDeep meta-registry, including all incident patients with complete hemodynamic profiles. Survival was evaluated using Kaplan-Meier and Cox proportional hazards models, adjusted for various confounders. Analyses included both PAH and non-PAH groups and risk assessment by the ESC/ERS 2022, REVEAL lite 2, and COMPERA 4-strata scores. All analyses were performed using R (The R Foundation). Results A total of 19,663 incident PH patients were included in the analysis, with 5,581 patients (28%) diagnosed with Group 1 PH and a median age of 64 years [IQR: 52-73]. Among these, male patients (8,704, 44%) had a significantly higher mortality risk than female patients across the entire cohort and within all PH subtypes. The adjusted hazard ratio for mortality in male versus female patients was 1.391 [95% CI: 1.260-1.536] in the overall population and 1.404 [95% CI: 1.264-1.561] for those with PAH. This survival difference was consistent across various severity levels, age groups, and in the presence of comorbidities such as obesity and cardiovascular diseases, as well as among those receiving PAH-specific therapies as well as patients who remained without treatment during the observation period. Notably, male disadvantage in survival was observed in low, intermediate, and high-risk categories for ESC/ERS 2022, REVEAL lite 2, and COMPERA scores but not within REVEAL 2.0, which includes male sex as a non-modifiable risk factor. Racial analysis revealed a greater mortality risk for males among White patients, with no significant differences noted in Black or Asian populations. Conclusion Our PVRI GoDeep meta-registry analysis demonstrates that male PH patients face higher mortality risk across both PAH and non-PAH groups, independent of disease etiology, age, severity, comorbidities, and treatment factors, with this risk amplified in White patients. These findings suggest that male sex should be further considered as a risk factor to refine predictive models for survival in PH.